|
Market Cap (24-May) $66,720,148 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (16-Jan) 98 (0.00%) (641st) |
|
52w High $0.099 |
52w Low $0.021 |
P/E 25.97 |
EPS 0 |
ACW released this announcement to the ASX on 9 January 2023, 8:49. The announcement is not marked as price sensitive, and is 30 page(s) in length and 1.54MB in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.084% short sold according to ASIC data. It was ranked the 486th most shorted stock on the ASX. It remains ranked 641st as of the latest reported data (16 January 2025).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| ACW CEO presentation Sachs Neuroscience and JPM week | 9 January 2023, 8:49 |
| Letter to Shareholders - CEO 2022 Review & Outlook | 22 December 2022, 14:10 |
| FDA agrees to six-month Phase 2b Alzheimers Disease Trial | 22 December 2022, 12:01 |
| Cleansing Notice | 9 December 2022, 10:48 |
You must be logged in to post a reply.
Actinogen Medical 